Loading...

Rosemary Akhurst, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentHDF Comprehensive Cancer Ctr
Address1450 3rd Street
San Francisco CA 94158
Phone415-514-0215
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Circulating cells as tools to study vascular pathobiology of HHT
    NIH R01HL122869Sep 1, 2015 - May 31, 2019
    Role: Principal Investigator
    Circulating cells as tools to study vascular pathobiology of HHT
    NIH R56HL122869Sep 15, 2014 - Aug 31, 2015
    Role: Principal Investigator
    Acquired Resistance to TGFBR1 inhibitors and cancer stem cell outgrowth
    NIH R21CA164772Apr 1, 2012 - Mar 31, 2014
    Role: Principal Investigator
    IVIS Spectrum Imaging System
    NIH S10RR031642Apr 15, 2011 - Apr 14, 2012
    Role: Principal Investigator
    "Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
    NIH R01CA116019May 1, 2007 - Jan 31, 2012
    Role: Principal Investigator
    Functional analysis of Tgfbm3 locus in vascular development and disease
    NIH R01HL078564Feb 16, 2006 - Jan 31, 2012
    Role: Principal Investigator
    Program Project Grant
    NIH P01AR050440Sep 26, 2003 - Aug 31, 2010
    Role: Co-Investigator
    TGFBM2 in Development and Disease
    NIH R01GM060514Feb 1, 2001 - Mar 31, 2014
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH P30CA082103Aug 5, 1999 - May 31, 2017
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Muthusamy BP, Budi EH, Katsuno Y, Lee MK, Smith SM, Mirza AM, Akhurst RJ, Derynck R. ShcA Protects against Epithelial-Mesenchymal Transition through Compartmentalized Inhibition of TGF-ß-Induced Smad Activation. PLoS Biol. 2015 Dec; 13(12):e1002325. PMID: 26680585.
      View in: PubMed
    2. Akhurst RJ, Padgett RW. Matters of context guide future research in TGFß superfamily signaling. Sci Signal. 2015; 8(399):re10. PMID: 26486175.
      View in: PubMed
    3. Letteboer TG, Benzinou M, Merrick CB, Quigley DA, Zhau K, Kim IJ, To MD, Jablons DM, van Amstel JK, Westermann CJ, Giraud S, Dupuis-Girod S, Lesca G, Berg JH, Balmain A, Akhurst RJ. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet. 2015; 6:67. PMID: 25815003; PMCID: PMC4357294.
    4. Kawasaki K, Freimuth J, Meyer DS, Lee MM, Tochimoto-Okamoto A, Benzinou M, Clermont FF, Wu G, Roy R, Letteboer TG, Ploos van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Westermann CJ, Coffey RJ, Akhurst RJ. Genetic variants of Adam17 differentially regulate TGFß signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):7723-8. PMID: 24812125; PMCID: PMC4040598.
    5. Derynck R, Akhurst RJ. BMP-9 balances endothelial cell fate. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):18746-7. PMID: 24222686; PMCID: PMC3839760.
    6. Kang HC, Quigley DA, Kim IJ, Wakabayashi Y, Ferguson-Smith MA, D'Alessandro M, Birgitte Lane E, Akhurst RJ, Goudie DR, Balmain A. Multiple self-healing squamous epithelioma (MSSE): rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology. J Invest Dermatol. 2013 Jul; 133(7):1907-10. PMID: 23358096; PMCID: PMC3664264.
    7. Freimuth J, Clermont FF, Huang X, DeSapio A, Tokuyasu TA, Sheppard D, Akhurst RJ. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc Natl Acad Sci U S A. 2012 Oct 30; 109(44):18042-7. PMID: 23064636; PMCID: PMC3497801.
    8. Akhurst RJ, Hata A. Targeting the TGFß signalling pathway in disease. Nat Rev Drug Discov. 2012 Oct; 11(10):790-811. PMID: 23000686; PMCID: PMC3520610.
    9. Akhurst RJ. The paradoxical TGF-ß vasculopathies. Nat Genet. 2012 Aug; 44(8):838-9. PMID: 22836090; PMCID: PMC3543110.
    10. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-ß targeted cancer therapy. Int J Biol Sci. 2012; 8(7):964-78. PMID: 22811618; PMCID: PMC3399319.
    11. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-ß-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012 Mar 1; 125(Pt 5):1259-73. PMID: 22399812; PMCID: PMC3324583.
    12. Arnold TD, Ferrero GM, Qiu H, Phan IT, Akhurst RJ, Huang EJ, Reichardt LF. Defective retinal vascular endothelial cell development as a consequence of impaired integrin aVß8-mediated activation of transforming growth factor-ß. J Neurosci. 2012 Jan 25; 32(4):1197-206. PMID: 22279205; PMCID: PMC3578416.
    13. Benzinou M, Clermont FF, Letteboer TG, Kim JH, Espejel S, Harradine KA, Arbelaez J, Luu MT, Roy R, Quigley D, Higgins MN, Zaid M, Aouizerat BE, van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Plauchu H, Hughes CC, Westermann CJ, Akhurst RJ. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun. 2012; 3:616. PMID: 22233626; PMCID: PMC3509798.
    14. Connolly EC, Akhurst RJ. The complexities of TGF-ß action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol. 2011 Dec; 12(12):2138-49. PMID: 21619543; PMCID: PMC3520605.
    15. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH. TGFß1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011 Nov 1; 17(21):6754-65. PMID: 22028490; PMCID: PMC3724539.
    16. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TßRI/II kinase inhibition with LY2109761. Cancer Res. 2011 Mar 15; 71(6):2339-49. PMID: 21282335; PMCID: PMC3059399.
    17. Akhurst RJ. Taking thalidomide out of rehab. Nat Med. 2010 Apr; 16(4):370-2. PMID: 20376039; PMCID: PMC2917634.
    18. Harradine KA, Ridd K, Saunier EF, Clermont FF, Perez-Losada J, Moore DH, Epstein EH, Bastian BC, Akhurst RJ. Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res. 2009 Aug 15; 15(16):5101-7. PMID: 19671862; PMCID: PMC2812428.
    19. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res. 2009; 11(1):202. PMID: 19291273; PMCID: PMC2687712.
    20. Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol. 2008 Jun; 10(6):654-64. PMID: 18469808; PMCID: PMC2649123.
    21. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007 Sep; 9(9):1000-4. PMID: 17762890.
      View in: PubMed
    22. Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets. 2006 Nov; 6(7):565-78. PMID: 17100564.
      View in: PubMed
    23. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs. 2006 Jun; 7(6):513-21. PMID: 16784021.
      View in: PubMed
    24. Mao JH, Saunier EF, de Koning JP, McKinnon MM, Higgins MN, Nicklas K, Yang HT, Balmain A, Akhurst RJ. Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc Natl Acad Sci U S A. 2006 May 23; 103(21):8125-30. PMID: 16702541; PMCID: PMC1472440.
    25. Akhurst RJ. A sweet link between TGFbeta and vascular disease? Nat Genet. 2006 Apr; 38(4):400-1. PMID: 16570059.
      View in: PubMed
    26. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, Balmain A, Akhurst RJ, Korn WM. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res. 2006 Feb 1; 66(3):1648-57. PMID: 16452224.
      View in: PubMed
    27. Poon E, Clermont F, Firpo MT, Akhurst RJ. TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development. J Cell Sci. 2006 Feb 15; 119(Pt 4):759-68. PMID: 16449320.
      View in: PubMed
    28. Harradine KA, Akhurst RJ. Mutations of TGFbeta signaling molecules in human disease. Ann Med. 2006; 38(6):403-14. PMID: 17008304.
      View in: PubMed
    29. Tang Y, Lee KS, Yang H, Logan DW, Wang S, McKinnon ML, Holt LJ, Condie A, Luu MT, Akhurst RJ. Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. Genomics. 2005 Jan; 85(1):60-70. PMID: 15607422.
      View in: PubMed
    30. Akhurst RJ. TGF beta signaling in health and disease. Nat Genet. 2004 Aug; 36(8):790-2. PMID: 15284845.
      View in: PubMed
    31. Balmain A, Akhurst RJ. Cancer: dangerous liaisons. Nature. 2004 Mar 18; 428(6980):271-2. PMID: 15029181.
      View in: PubMed
    32. Chan CK, Pham LN, Chinn C, Spee C, Ryan SJ, Akhurst RJ, Hinton DR. Mouse strain-dependent heterogeneity of resting limbal vasculature. Invest Ophthalmol Vis Sci. 2004 Feb; 45(2):441-7. PMID: 14744883.
      View in: PubMed
    33. Tang Y, McKinnon ML, Leong LM, Rusholme SA, Wang S, Akhurst RJ. Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice. Hum Mol Genet. 2003 Jul 1; 12(13):1579-89. PMID: 12812985.
      View in: PubMed
    34. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, Akhurst RJ, Barcellos-Hoff MH. Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res. 2002 Oct 15; 62(20):5627-31. PMID: 12384514.
      View in: PubMed
    35. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol. 2002 Jul; 4(7):487-94. PMID: 12105419.
      View in: PubMed
    36. Akhurst RJ. TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest. 2002 Jun; 109(12):1533-6. PMID: 12070299; PMCID: PMC151022.
    37. Ewan KB, Shyamala G, Ravani SA, Tang Y, Akhurst R, Wakefield L, Barcellos-Hoff MH. Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am J Pathol. 2002 Jun; 160(6):2081-93. PMID: 12057913; PMCID: PMC1850834.
    38. Akhurst RJ, Derynck R. TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001 Nov; 11(11):S44-51. PMID: 11684442.
      View in: PubMed
    39. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001 Oct; 29(2):117-29. PMID: 11586292.
      View in: PubMed
    40. Akhurst RJ, Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol. 1999 Jan; 187(1):82-90. PMID: 10341708.
      View in: PubMed
    41. Frame S, Crombie R, Liddell J, Stuart D, Linardopoulos S, Nagase H, Portella G, Brown K, Street A, Akhurst R, Balmain A. Epithelial carcinogenesis in the mouse: correlating the genetics and the biology. Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29; 353(1370):839-45. PMID: 9684281; PMCID: PMC1692278.
    42. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, Balmain A. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ. 1998 May; 9(5):393-404. PMID: 9607560.
      View in: PubMed
    43. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M, Akhurst RJ. Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat Genet. 1997 Feb; 15(2):207-11. PMID: 9020852.
      View in: PubMed
    44. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 1996 Aug 23; 86(4):531-42. PMID: 8752208.
      View in: PubMed
    45. Fowlis DJ, Cui W, Johnson SA, Balmain A, Akhurst RJ. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor beta 1 in the skin of transgenic mice. Cell Growth Differ. 1996 May; 7(5):679-87. PMID: 8732677.
      View in: PubMed
    46. Bonyadi M, Cui W, Nagase H, Akhurst RJ. The TGF beta type II receptor, Tgfbr2, maps to distal mouse chromosome 9. Genomics. 1996 Apr 15; 33(2):328-9. PMID: 8660988.
      View in: PubMed
    47. Alexander MY, Akhurst RJ. Liposome-medicated gene transfer and expression via the skin. Hum Mol Genet. 1995 Dec; 4(12):2279-85. PMID: 8634699.
      View in: PubMed
    48. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 1995 Jun; 121(6):1845-54. PMID: 7600998.
      View in: PubMed
    49. Alexander MY, Bidichandani SI, Cousins FM, Robinson CJ, Duffie E, Akhurst RJ. Circulating human factor IX produced in keratin-promoter transgenic mice: a feasibility study for gene therapy of haemophilia B. Hum Mol Genet. 1995 Jun; 4(6):993-9. PMID: 7544665.
      View in: PubMed
    50. Cui W, Fowlis DJ, Cousins FM, Duffie E, Bryson S, Balmain A, Akhurst RJ. Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev. 1995 Apr 15; 9(8):945-55. PMID: 7774812.
      View in: PubMed
    51. Martin JS, Dickson MC, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Analysis of homozygous TGF beta 1 null mouse embryos demonstrates defects in yolk sac vasculogenesis and hematopoiesis. Ann N Y Acad Sci. 1995 Mar 27; 752:300-8. PMID: 7755275.
      View in: PubMed
    52. Cui W, Kemp CJ, Duffie E, Balmain A, Akhurst RJ. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion. Cancer Res. 1994 Nov 15; 54(22):5831-6. PMID: 7954410.
      View in: PubMed
    53. Watts P, Stables GS, Akhurst RJ, Mackie RM. Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy. Br J Dermatol. 1994 Jul; 131(1):64-71. PMID: 7519033.
      View in: PubMed
    54. Dickson MC, Slager HG, Duffie E, Mummery CL, Akhurst RJ. RNA and protein localisations of TGF beta 2 in the early mouse embryo suggest an involvement in cardiac development. Development. 1993 Feb; 117(2):625-39. PMID: 7687212.
      View in: PubMed
    55. Brown K, Kemp CJ, Burns PA, Stoler AB, Fowlis DJ, Akhurst RJ, Balmain A. Positive and negative growth control in multistage skin carcinogenesis. Recent Results Cancer Res. 1993; 128:309-21. PMID: 8356328.
      View in: PubMed
    56. Martin P, Dickson MC, Millan FA, Akhurst RJ. Rapid induction and clearance of TGF beta 1 is an early response to wounding in the mouse embryo. Dev Genet. 1993; 14(3):225-38. PMID: 8358867.
      View in: PubMed
    57. Akhurst R, Fitzpatrick DR, Fowlis DJ, Gatherer D, Millan FA, Slager H. The role of TGF-beta s in mammalian development and neoplasia. Mol Reprod Dev. 1992 Jun; 32(2):127-35. PMID: 1637551.
      View in: PubMed
    58. Fowlis DJ, Flanders KC, Duffie E, Balmain A, Akhurst R. Discordant transforming growth factor beta 1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ. 1992 Feb; 3(2):81-91. PMID: 1504019.
      View in: PubMed
    59. Haddow S, Fowlis DJ, Parkinson K, Akhurst R, Balmain A. Loss of growth control by TGF-beta occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation. Oncogene. 1991 Aug; 6(8):1465-70. PMID: 1886717.
      View in: PubMed
    60. Millan FA, Denhez F, Kondaiah P, Akhurst R. Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo. Development. 1991 Jan; 111(1):131-43. PMID: 1707784.
      View in: PubMed
    61. Balmain A, Kemp CJ, Burns PA, Stoler AB, Fowlis DJ, Akhurst R. Functional loss of tumour suppressor genes in multistage chemical carcinogenesis. Princess Takamatsu Symp. 1991; 22:97-108. PMID: 1844254.
      View in: PubMed
    62. Gatherer D, Ten Dijke P, Baird DT, Akhurst R. Expression of TGF-beta isoforms during first trimester human embryogenesis. Development. 1990 Oct; 110(2):445-60. PMID: 2133548.
      View in: PubMed
    63. Turbitt ML, Akhurst R, White SI, MacKie RM. Localization of elevated transforming growth factor-alpha in psoriatic epidermis. J Invest Dermatol. 1990 Aug; 95(2):229-32. PMID: 2380581.
      View in: PubMed
    64. Akhurst R, Lehnert SA, Gatherer D, Duffie E. The role of TGF beta in mouse development. Ann N Y Acad Sci. 1990; 593:259-71. PMID: 1695826.
      View in: PubMed
    65. Bailleul B, Brown K, Ramsden M, Akhurst R, Fee F, Balmain A. Chemical induction of oncogene mutations and growth factor activity in mouse skin carcinogenesis. Environ Health Perspect. 1989 May; 81:23-7. PMID: 2667981; PMCID: PMC1567527.
    66. Akhurst R, Bailleul B, Brown K, Ramsden M, Fee F, Balmain A. The action of oncogenes and growth factors in tumour initiation and promotion. Carcinog Compr Surv. 1989; 11:243-55. PMID: 2493336.
      View in: PubMed
    67. Balmain A, Brown K, Akhurst R, Fee FM. Molecular analysis of chemical carcinogenesis in the skin. Br J Cancer Suppl. 1988 Dec; 9:72-5. PMID: 3076069; PMCID: PMC2149109.
    68. Lehnert SA, Akhurst R. Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action. Development. 1988 Oct; 104(2):263-73. PMID: 2474426.
      View in: PubMed
    69. Akhurst RJ, Fee F, Balmain A. Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature. 1988 Jan 28; 331(6154):363-5. PMID: 3422343.
      View in: PubMed
    70. Minor JE, Lee JJ, Akhurst RJ, Leahy PS, Britten RJ, Davidson EH. Sea urchin actin gene linkages determined by genetic segregation. Dev Biol. 1987 Jul; 122(1):291-5. PMID: 2885237.
      View in: PubMed
    71. Akhurst RJ, Calzone FJ, Lee JJ, Britten RJ, Davidson EH. Structure and organization of the CyIII actin gene subfamily of the sea urchin, Strongylocentrotus purpuratus. J Mol Biol. 1987 Mar 20; 194(2):193-203. PMID: 3612803.
      View in: PubMed
    72. Lee JJ, Shott RJ, Rose SJ, Thomas TL, Britten RJ, Davidson EH. Sea urchin actin gene subtypes. Gene number, linkage and evolution. J Mol Biol. 1984 Jan 15; 172(2):149-76. PMID: 6319714.
      View in: PubMed
    73. Akhurst R, Shott RJ, Lee JJ, Britten RJ, Davidson EH. Dev. Biol. Differential expression of the actin gene family of Strongylocentrotus purpuratus. 1984; 101(2):295-306.
    74. Birnie GD, Jacobs H, Shott R, Wilkes PR. Regulation of the relative abundances of mRNAs in hepatoma and liver. Adv Exp Med Biol. 1982; 158:387-94. PMID: 6186132.
      View in: PubMed
    75. Birnie GD, Balmain A, Jacobs H, Shott R, Wilkes PR, Paul J. Post-transcriptional control of messenger abundance. Mol Biol Rep. 1981 May 22; 7(1-3):159-62. PMID: 6114395.
      View in: PubMed
    Back to TOP